Fluacizine

Fluacizine
Skeletal formula of fluacizine
Space-filling model of the fluacizine molecule
Clinical data
Trade namesPhtorazisin
Other namesFluoracizine; Fluoracyzine; Fluoracisine; Ftoracizin; Ftoracizine; Phthoracizin
Routes of
administration
Oral, intramuscular injection
ATC code
  • None
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 3-Diethylamino-1-[2-(trifluoromethyl)phenothiazin-10-yl]-propan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H21F3N2OS
Molar mass394.46 g·mol−1
3D model (JSmol)
  • FC(F)(F)c2cc1N(c3c(Sc1cc2)cccc3)C(=O)CCN(CC)CC
  • InChI=1S/C20H21F3N2OS/c1-3-24(4-2)12-11-19(26)25-15-7-5-6-8-17(15)27-18-10-9-14(13-16(18)25)20(21,22)23/h5-10,13H,3-4,11-12H2,1-2H3 checkY
  • Key:VHEOUJNDDFHPGJ-UHFFFAOYSA-N checkY
  (verify)

Fluacizine, sold under the brand name Phtorazisin, is a tricyclic antidepressant (TCA) of the phenothiazine group which is or was marketed in Russia. Unlike other phenothiazines, fluacizine is not an antipsychotic, and can actually reverse catalepsy and extrapyramidal symptoms induced by antidopaminergic agents like antipsychotics, reserpine, and tetrabenazine as well as potentiate amphetamine-induced stereotypy. It is known to act as a norepinephrine reuptake inhibitor, antihistamine, and anticholinergic. The drug was developed in the 1960s and was marketed in the 1970s. It is the trifluoromethyl analogue of chloracizine.

See also